{"transactions":[{"id":704185,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2026-07-23T20:10:06.000Z","date":"2026-07-21","kind":"purchase","planned":false,"acquired":true,"shares":36000,"price":0.69,"value":24840.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.688 to $0.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":2119334,"source":{"system":"sec-edgar","filing":"0001031686-26-000006","document":"form4-07232026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000103168626000006/form4-07232026_040701.xml","form_type":"4"}},{"id":757622,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-06-01T20:09:53.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":123600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the \"2021 Plan\")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date."}],"balance_after":123600,"derivative":{"exercise_price":0.9515,"expiration_date":"2036-05-27","underlying":"Class A Common Stock","underlying_shares":123600},"source":{"system":"sec-edgar","filing":"0001031686-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000103168626000004/ownership.xml","form_type":"4"}},{"id":1013361,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Class A Common Stock","published_at":"2025-10-27T23:24:25.000Z","date":"2025-10-23","kind":"purchase","planned":false,"acquired":true,"shares":2083334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The warrants shall be exercisable upon stockholder approval and have a term of exercise equal to five years from the date of such stockholder approval."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The warrants shall be exercisable upon stockholder approval and have a term of exercise equal to five years from the date of such stockholder approval."}],"balance_after":2083334,"derivative":{"exercise_price":0.48,"underlying":"Class A Common Stock","underlying_shares":2083334},"source":{"system":"sec-edgar","filing":"0001031686-25-000004","document":"form4-10272025_111021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000103168625000004/form4-10272025_111021.xml","form_type":"4"}},{"id":1013360,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2025-10-27T23:24:25.000Z","date":"2025-10-23","kind":"purchase","planned":false,"acquired":true,"shares":2083334,"price":0.605,"value":1260417.07,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person purchased these shares in a PIPE offering conducted by the Issuer."}],"balance_after":2083334,"source":{"system":"sec-edgar","filing":"0001031686-25-000004","document":"form4-10272025_111021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000103168625000004/form4-10272025_111021.xml","form_type":"4"}},{"id":1129634,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-05-30T21:57:02.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan)."}],"balance_after":50000,"derivative":{"exercise_price":0.62,"expiration_date":"2035-05-27","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-015038","document":"form4-05302025_090553.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000141588925015038/form4-05302025_090553.xml","form_type":"4"}},{"id":1329471,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-17T22:00:04.000Z","date":"2024-12-16","kind":"grant","planned":false,"acquired":true,"shares":101276,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options."}],"balance_after":101276,"derivative":{"exercise_price":4.11,"exercise_date":"2024-05-25","expiration_date":"2033-05-24","underlying":"Class A Common Stock","underlying_shares":101276},"source":{"system":"sec-edgar","filing":"0000950170-24-137314","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000095017024137314/ownership.xml","form_type":"4"}},{"id":1329470,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-17T22:00:04.000Z","date":"2024-12-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":101276,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options."}],"balance_after":0,"derivative":{"exercise_price":2.84,"exercise_date":"2024-05-25","expiration_date":"2033-05-24","underlying":"Class A Common Stock","underlying_shares":101276},"source":{"system":"sec-edgar","filing":"0000950170-24-137314","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000095017024137314/ownership.xml","form_type":"4"}},{"id":1498299,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-30T20:48:33.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan)."}],"balance_after":50000,"derivative":{"exercise_price":5,"expiration_date":"2034-05-28","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-066722","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000095017024066722/ownership.xml","form_type":"4"}},{"id":1705492,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-19T21:05:06.000Z","date":"2023-12-16","kind":"grant","planned":false,"acquired":true,"shares":101276,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 16, 2023 (the \"Repricing Date\"). Pursuant to\nthe Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's\nCommon Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan)."}],"balance_after":101276,"derivative":{"exercise_price":2.84,"expiration_date":"2033-05-24","underlying":"Class A Common Stock","underlying_shares":101276},"source":{"system":"sec-edgar","filing":"0000950170-23-071465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000095017023071465/ownership.xml","form_type":"4"}},{"id":1705491,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-19T21:05:06.000Z","date":"2023-12-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":101276,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 16, 2023 (the \"Repricing Date\"). Pursuant to\nthe Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's\nCommon Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan)."}],"balance_after":0,"derivative":{"exercise_price":4.11,"expiration_date":"2033-05-24","underlying":"Class A Common Stock","underlying_shares":101276},"source":{"system":"sec-edgar","filing":"0000950170-23-071465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000095017023071465/ownership.xml","form_type":"4"}},{"id":1875271,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-31T00:10:01.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":101276,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan)."}],"balance_after":101276,"derivative":{"exercise_price":4.11,"expiration_date":"2033-05-24","underlying":"Class A Common Stock","underlying_shares":101276},"source":{"system":"sec-edgar","filing":"0001209191-23-033048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000120919123033048/doc4.xml","form_type":"4"}},{"id":2174134,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common LLC Units","published_at":"2022-08-26T01:14:32.000Z","date":"2022-08-23","kind":"exercise","acquired":false,"shares":7694,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units (\"LLC Units\"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer (\"Class B Shares\") for newly-issued shares of Class A Common Stock of the Issuer (\"Class A Shares\")."},{"field":"shares","element":"transactionShares","label":"F5","text":"The Reporting Person is a General Partner of Rani Investment Corp. Represents 7,694 LLC Units previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units (\"LLC Units\"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer (\"Class B Shares\") for newly-issued shares of Class A Common Stock of the Issuer (\"Class A Shares\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units (\"LLC Units\"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer (\"Class B Shares\") for newly-issued shares of Class A Common Stock of the Issuer (\"Class A Shares\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person is a General Partner of InCube Ventures II, L.P., and InCube Labs, LLC is wholly-owned by the Reporting Person and his family. Represents 22,411,124 LLC Units Shares held by InCube Labs, LLC and 248,929 LLC Units held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":22660053,"derivative":{"exercise_price":0,"underlying":"Class A Common Stock","underlying_shares":7694},"source":{"system":"sec-edgar","filing":"0001209191-22-047661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000120919122047661/doc4.xml","form_type":"4"}},{"id":2174133,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-26T01:14:32.000Z","date":"2022-08-23","kind":"exercise","acquired":true,"shares":7694,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units (\"LLC Units\"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer (\"Class B Shares\") for newly-issued shares of Class A Common Stock of the Issuer (\"Class A Shares\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. InCube Labs, L.L.C. is wholly-owned by the Reporting Person and his family. Represents 52,781 shares of Class A Common Stock of the Issuer held by InCube Ventures II, L.P., 13,664 shares of Class A Common Stock of the Issuer held by InCube Labs, L.L.C., and 7,694 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":74139,"source":{"system":"sec-edgar","filing":"0001209191-22-047661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000120919122047661/doc4.xml","form_type":"4"}},{"id":2174132,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2022-08-26T01:14:32.000Z","date":"2022-08-23","kind":"exercise","acquired":false,"shares":7694,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units (\"LLC Units\"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer (\"Class B Shares\") for newly-issued shares of Class A Common Stock of the Issuer (\"Class A Shares\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person is a General Partner of Rani Investment Corp. Represents 7,694 Class B Shares previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a General Partner of InCube Ventures II, L.P., and InCube Labs, LLC is wholly-owned by the Reporting Person and his family. Represents 22,411,124 Class B Shares held by InCube Labs, LLC and 248,929 Class B Shares held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":22660053,"source":{"system":"sec-edgar","filing":"0001209191-22-047661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000120919122047661/doc4.xml","form_type":"4"}},{"id":2178544,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-20T00:05:07.000Z","date":"2022-08-17","kind":"sale","acquired":false,"shares":9210,"price":11.62,"value":107020.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is a General Partner of Rani Investment Corp. Represents Class A Shares held by Rani Investment Corp."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.39 to $11.975, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a General Partner of InCube Ventures II, L.P. InCube Labs, L.L.C. is wholly-owned by the Reporting Person and his family. Represents 52,781 shares of Class A Common Stock of the Issuer held by InCube Ventures II, L.P. and 13,664 shares of Class A Common Stock of the Issuer held by InCube Labs, L.L.C. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":66445,"source":{"system":"sec-edgar","filing":"0001209191-22-046958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000120919122046958/doc4.xml","form_type":"4"}},{"id":2178543,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-08-20T00:05:07.000Z","date":"2022-08-17","kind":"sale","acquired":false,"shares":71042,"price":10.51,"value":746651.42,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is a General Partner of Rani Investment Corp. Represents Class A Shares held by Rani Investment Corp."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.39 to $11.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. InCube Labs, L.L.C. is wholly-owned by the Reporting Person and his family. Represents 52,781 shares of Class A Common Stock of the Issuer held by InCube Ventures II, L.P., 13,664 shares of Class A Common Stock of the Issuer held by InCube Labs, L.L.C., and 9,210 shares of Class A Common Stock of the Issuer held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":75655,"source":{"system":"sec-edgar","filing":"0001209191-22-046958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000120919122046958/doc4.xml","form_type":"4"}},{"id":2254002,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T12:30:11.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":41416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan)."}],"balance_after":41416,"derivative":{"exercise_price":10.89,"expiration_date":"2032-05-24","underlying":"Class A Common Stock","underlying_shares":41416},"source":{"system":"sec-edgar","filing":"0000899243-22-019853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000089924322019853/doc4.xml","form_type":"4"}},{"id":2340225,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common LLC Units","published_at":"2022-03-11T01:12:04.000Z","date":"2022-03-07","kind":"exercise","acquired":false,"shares":2309490,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units (\"LLC Units\"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer (\"Class B Shares\") for newly-issued shares of Class A Common Stock of the Issuer (\"Class A Shares\")."},{"field":"shares","element":"transactionShares","label":"F6","text":"The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 LLC Units previously held by InCube Ventures II, L.P. and 80,252 LLC Units previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units (\"LLC Units\"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer (\"Class B Shares\") for newly-issued shares of Class A Common Stock of the Issuer (\"Class A Shares\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units (\"LLC Units\"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer (\"Class B Shares\") for newly-issued shares of Class A Common Stock of the Issuer (\"Class A Shares\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 LLC Units previously held by InCube Ventures II, L.P. and 80,252 LLC Units previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":22667747,"derivative":{"exercise_price":0,"underlying":"Class A Common Stock","underlying_shares":2309490},"source":{"system":"sec-edgar","filing":"0001179110-22-002126","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000117911022002126/edgar.xml","form_type":"4"}},{"id":2340224,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-03-11T01:12:04.000Z","date":"2022-03-07","kind":"other","acquired":false,"shares":2229238,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"InCube Ventures II, L.P. distributed these shares to its limited partners on a pro rata basis, for no consideration"},{"field":"shares","element":"transactionShares","label":"F5","text":"The Reporting Person is a General Partner of InCube Ventures II, L.P. Represents 2,229,238 Class A Shares previously held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a General Partner of InCube Ventures II, L.P. Represents 2,229,238 Class A Shares previously held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":147959,"source":{"system":"sec-edgar","filing":"0001179110-22-002126","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000117911022002126/edgar.xml","form_type":"4"}},{"id":2340223,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-03-11T01:12:04.000Z","date":"2022-03-07","kind":"exercise","acquired":true,"shares":2309490,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units (\"LLC Units\"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer (\"Class B Shares\") for newly-issued shares of Class A Common Stock of the Issuer (\"Class A Shares\")."},{"field":"shares","element":"transactionShares","label":"F4","text":"The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class A Shares held by InCube Ventures II, L.P. and 80,252 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class A Shares held by InCube Ventures II, L.P. and 80,252 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":2377197,"source":{"system":"sec-edgar","filing":"0001179110-22-002126","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000117911022002126/edgar.xml","form_type":"4"}},{"id":2340222,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2022-03-11T01:12:04.000Z","date":"2022-03-07","kind":"exercise","acquired":false,"shares":2309490,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units (\"LLC Units\"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer (\"Class B Shares\") for newly-issued shares of Class A Common Stock of the Issuer (\"Class A Shares\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class B Shares previously held by InCube Ventures II, L.P. and 80,252 Class B Shares previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class B Shares previously held by InCube Ventures II, L.P. and 80,252 Class B Shares previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":22667747,"source":{"system":"sec-edgar","filing":"0001179110-22-002126","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000117911022002126/edgar.xml","form_type":"4"}},{"id":2410412,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-02-08T02:49:10.000Z","date":"2022-02-03","kind":"other","acquired":true,"shares":67707,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"InCube Ventures II, L.P., is the limited partner of Biologix Partners, LP and VH Rani, LP. InCube Ventures II, L.P. therefore received 12,289 Class A Shares distributed by Biologix Partners, LP and 41,495 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"shares","element":"transactionShares","label":"F4","text":"InCube Labs, L.L.C., is the limited partner of Biologix Partners, LP and VH Rani, LP. InCube Labs, L.L.C. therefore received 3,181 Class A Shares distributed by Biologix Partners, LP and 10,742 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"InCube Ventures II, L.P., is the limited partner of Biologix Partners, LP and VH Rani, LP. InCube Ventures II, L.P. therefore received 12,289 Class A Shares distributed by Biologix Partners, LP and 41,495 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"InCube Labs, L.L.C., is the limited partner of Biologix Partners, LP and VH Rani, LP. InCube Labs, L.L.C. therefore received 3,181 Class A Shares distributed by Biologix Partners, LP and 10,742 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."}],"balance_after":67707,"source":{"system":"sec-edgar","filing":"0001209191-22-007642","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000120919122007642/doc4.xml","form_type":"4"}},{"id":2410411,"issuer":{"id":6642,"kind":"organization","name":"Rani Therapeutics Holdings, Inc.","symbol":"RANI"},"owners":[{"id":29032,"kind":"person","name":"IMRAN MIR A","position":1,"cik":"0001031686","reported_name":"IMRAN MIR A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-02-08T02:49:10.000Z","date":"2022-02-03","kind":"other","acquired":false,"shares":827467,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Biologix Partners, LP and VH Rani, LP. distributed these shares to its limited partners on a pro rata basis, for no consideration."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents previously held 378,564 shares of Class A Common Stock of the Issuer (\"Class A Shares\") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents previously held 378,564 shares of Class A Common Stock of the Issuer (\"Class A Shares\") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-007642","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1031686/000120919122007642/doc4.xml","form_type":"4"}}]}